Measurement of the intracellular active metabolites of thiopurine drugs to evaluate the enzymatic activity of nudix hydrolase 15 in human blood samples.

Enzyme activity Liquid chromatography-mass spectrometry Nudix hydrolase 15 Peripheral blood mononuclear cells Thioguanine nucleotides Thiopurine

Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
18 Jan 2024
Historique:
received: 07 04 2023
revised: 13 12 2023
accepted: 01 01 2024
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 21 1 2024
Statut: aheadofprint

Résumé

Thiopurine is metabolized to 6-thio-(deoxy) guanosine triphosphate (6-thio-(d) GTP), which is then incorporated into DNA or RNA and causes cytotoxicity. Nudix hydrolase 15 (NUDT15) reduces the cytotoxic effects of thiopurine by converting 6-thio-(d) GTP to 6-thio-(d) guanosine monophosphate (6-thio-(d) GMP). NUDT15 polymorphisms like the Arg139Cys variant are strongly linked to thiopurine-induced severe leukocytopenia and alopecia. Therefore, measurement of NUDT15 enzymatic activity in individual patients can help predict thiopurine tolerability and adjust the dosage. We aimed to develop a quantitative assay for NUDT15 enzymatic activity in human blood samples. Blood samples were collected from donors whose NUDT15 genetic status was determined. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to assess the 6-thio-GTP metabolic activity in cell extracts. Because 6-thio-guanosine diphosphate (6-thio-GDP) and 6-thio-GMP were generated upon incubation of 6-thio-GTP with human blood cell extracts, the method detecting 6-thio-GTP, 6-thio-GDP, and 6-thio-GMP was validated. All three metabolites were linearly detected, and the lower limit of quantification (LLOQ) of 6-thio-GTP, 6-thio-GDP, and 6-thio-GMP were 5 μM, 1 μM, and 2 μM, respectively. Matrix effects of human blood cell extracts to detect 6-thio-GTP, 6-thio-GDP, and 6-thio-GMP were 99.0 %, 100.5 %, and 101.4 %, respectively, relative to the signals in the absence of blood cell extracts. The accuracy and precision of the method and the stability of the samples were also assessed. Using this established method, the genotype-dependent differences in NUDT15 activities were successfully determined using cell extracts derived from human blood cells with NUDT15 wild-type (WT) or Arg139Cys variant and 6-thio-GTP (100 μM) as a substrate (18.1, 14.9, and 6.43 μM/h/10

Identifiants

pubmed: 38246006
pii: S1570-0232(24)00001-1
doi: 10.1016/j.jchromb.2024.123993
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123993

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Yusuke Miyatani reports financial support was provided by Japan Foundation for Applied Enzymology].

Auteurs

Hitomi Okamoto (H)

Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Japan; Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.

Yoichi Tanaka (Y)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan; Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, Japan. Electronic address: tanakayoichi@nihs.go.jp.

Yoshio Shibagaki (Y)

Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Japan.

Satoshi Kuronuma (S)

Biomedical Laboratory, Department of Research, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Yusuke Miyatani (Y)

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan; Department of Gastroenterology and Hepatology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Satoko Umeda (S)

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan; Department of Gastroenterology and Hepatology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Emi Mishiro-Sato (E)

Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Japan.

Osamu Takeuchi (O)

Biomedical Laboratory, Department of Research, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Seisuke Hattori (S)

Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Japan.

Taku Kobayashi (T)

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan; Department of Gastroenterology and Hepatology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Mitsuru Okuwaki (M)

Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Japan. Electronic address: okuwakim@pharm.kitasato-u.ac.jp.

Classifications MeSH